In recent years, series of driver genes, such as EGFR, KRAS/NRAS, BRAF, PIK3CA, ALK and ROS1 and so on, have been found in non-small cell lung cancer (NSCLC) one after another with the development of molecular detecting technology. Targeted drugs bring benefits for these NSCLC patients with driver gene variations. However, some NSCLC did not have any known driver gene variations; we called it pan-negative lung cancer. In this paper, we summarize the concept, clinical pathological characteristics, the epidemiological characteristics, treatment and prognosis of pan-negative NSCLC.
近年来随着对肿瘤驱动基因的不断探索和分子检测技术的快速发展，在非小细胞肺癌（non-small cell lung cancer, NSCLC）领域，一系列的驱动基因如EGFR、KRAS、BRAF、PIK3CA、ALK和ROS-1等相继被发现，并逐渐研发出相应的针对特定驱动基因变异的靶向治疗药物，使NSCLC患者的生存得到极大改善。尽管如此，仍有部分NSCLC患者未能检测到任何已知驱动基因变异，称之为pan-negative型NSCLC。本文就pan-negative型NSCLC的概念、临床病理和流行病学特点以及治疗预后等作一综述。.
Keywords: Driver gene; Lung neoplasms; Pan-negative.